ESMO
This work evaluates performance of a reflex cfDNA methylation–based MCED assay through Harbinger’s Cancer Origin Epigenetics–Harbinger Health (CORE-HH) study. Results demonstrate high specificity and clinically meaningful sensitivity across multiple cancers that lack effective screening options, supporting a scalable strategy for earlier cancer detection in asymptomatic populations.
